Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

被引:179
作者
Cortes, Jorge E.
Jones, Dan
O'Brien, Susan
Jabbour, Elias
Ravandi, Farhad
Koller, Charles
Borthakur, Gautam
Walker, Brenda
Zhao, Weiqiang
Shan, Jianqin
Kantarjian, Hagop
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia & Hematopathol, Houston, TX 77030 USA
[2] Ohio State Med Ctr, Dept Pathol, Columbus, OH USA
关键词
CHRONIC MYELOGENOUS LEUKEMIA; ALPHA PLUS CYTARABINE; IMATINIB MESYLATE; CYTOGENETIC RESPONSES; MOLECULAR RESPONSES; KINASE INHIBITOR; INTERFERON; RESISTANCE; BMS-354825; EFFICACY;
D O I
10.1200/JCO.2009.25.4920
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Dasatinib is effective therapy for chronic myeloid leukemia (CML) after imatinib failure. In this study, we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic phase. Patients and Methods Patients with newly diagnosed CML in early chronic phase were randomly assigned to receive dasatinib 100 mg once daily or 50 mg twice daily as initial therapy. Results Among 50 patients observed for at least 3 months, 49 patients (98%) achieved a complete cytogenetic response (CCyR), and 41 patients (82%) achieved a major molecular response (MMR). Responses occurred rapidly, with 94% of patients achieving CCyR by 6 months. There was no difference in response rate by treatment arm. The projected event-free survival rate at 24 months is 88%, and all patients are alive after a median follow-up time of 24 months. Grade >= 3 neutropenia and thrombocytopenia occurred in 21% and 10% of patients, respectively. Nonhematologic toxicity was usually grade 1 to 2. There was no significant difference in toxicity between the two arms, and the actual median dose at 12 months was 100 mg (range, 20 to 100 mg). Conclusion Dasatinib is an effective agent for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR.
引用
收藏
页码:398 / 404
页数:7
相关论文
共 25 条
[1]   Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia [J].
Baccarani, M ;
Martinelli, G ;
Rosti, G ;
Trabacchi, E ;
Testoni, N ;
Bassi, S ;
Amabile, M ;
Soverini, S ;
Castagnetti, F ;
Cilloni, D ;
Izzo, B ;
de Vivo, A ;
Messa, E ;
Bonifazi, F ;
Poerio, A ;
Luatti, S ;
Giugliano, E ;
Alberti, D ;
Fincato, G ;
Russo, D ;
Pane, F ;
Saglio, G .
BLOOD, 2004, 104 (13) :4245-4251
[2]   Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].
Baccarani, Michele ;
Saglio, Giuseppe ;
Goldman, John ;
Hochhaus, Andreas ;
Simonsson, Bengt ;
Appelbaum, Frederick ;
Apperley, Jane ;
Cervantes, Francisco ;
Cortes, Jorge ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Frangois ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Niederwieser, Dielger ;
Silver, Richard ;
Hehlmann, Rudiger .
BLOOD, 2006, 108 (06) :1809-1820
[3]   Comparison of imatinib, mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen:: high efficacy of drug combinations [J].
Bradeen, Heather A. ;
Eide, Christopher A. ;
O'Hare, Thomas ;
Johnson, Kara J. ;
Willis, Stephanie G. ;
Lee, Francis Y. ;
Druker, Brian J. ;
Deininger, Michael W. .
BLOOD, 2006, 108 (07) :2332-2338
[4]   Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate [J].
Cortes, J ;
Talpaz, M ;
O'Brien, S ;
Jones, D ;
Luthra, R ;
Shan, J ;
Giles, F ;
Faderl, S ;
Verstovsek, S ;
Garcia-Manero, G ;
Rios, MB ;
Kantarjian, H .
CLINICAL CANCER RESEARCH, 2005, 11 (09) :3425-3432
[5]  
CORTES J, 2008, BLOOD, V112, P1098
[6]  
Cortes Jorge, 2008, J Natl Compr Canc Netw, V6 Suppl 2, pS22
[7]   High-Dose Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: High Rates of Rapid Cytogenetic and Molecular Responses [J].
Cortes, Jorge E. ;
Kantarjian, Hagop M. ;
Goldberg, Stuart L. ;
Powell, Bayard L. ;
Giles, Francis J. ;
Wetzler, Meir ;
Akard, Luke ;
Burke, John M. ;
Kerr, Robert ;
Saleh, Mansoor ;
Salvado, August ;
McDougall, Karen ;
Albitar, Maher ;
Radich, Jerald .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4754-4759
[8]   Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis [J].
de Lavallade, Hugues ;
Apperley, Jane F. ;
Khorashad, Jamshid S. ;
Milojkovic, Dragana ;
Reid, Alistair G. ;
Bua, Marco ;
Szydlo, Richard ;
Olavarria, Eduardo ;
Kaeda, Jaspal ;
Goldman, John M. ;
Marin, David .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (20) :3358-3363
[9]   Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].
Druker, Brian J. ;
Guilhot, Francois ;
O'Brien, Stephen G. ;
Gathmann, Insa ;
Kantarjian, Hagop ;
Gattermann, Norbert ;
Deininger, Michael W. N. ;
Silver, Richard T. ;
Goldman, John M. ;
Stone, Richard M. ;
Cervantes, Francisco ;
Hochhaus, Andreas ;
Powell, Bayard L. ;
Gabrilove, Janice L. ;
Rousselot, Philippe ;
Reiffers, Josy ;
Cornelissen, Jan J. ;
Hughes, Timothy ;
Agis, Hermine ;
Fischer, Thomas ;
Verhoef, Gregor ;
Shepherd, John ;
Saglio, Giuseppe ;
Gratwohl, Alois ;
Nielsen, Johan L. ;
Radich, Jerald P. ;
Simonsson, Bengt ;
Taylor, Kerry ;
Baccarani, Michele ;
So, Charlene ;
Letvak, Laurie ;
Larson, Richard A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417
[10]   Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy [J].
Guilhot, Francois ;
Larson, Richard A. ;
O'Brien, Stephen G. ;
Gathmann, Insa ;
Druker, Brian J. .
BLOOD, 2007, 110 (11) :16A-16A